Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease

20221,259 citationsJournal Articlediamond Open Access

Authors

Samantha Budd Haeberlein · Biogen (United States)

Paul Aisen · University of Southern California

Frederik Barkhof · National Hospital for Neurology and Neurosurgery

Spyros Chalkias · Biogen (United States)

Tianle Chen · Biogen (United States)

Sarah Cohen

Gersham Dent · Biogen (United States)

Abstract

Data from EMERGE demonstrated a statistically significant change across all four primary and secondary clinical endpoints. ENGAGE did not meet its primary or secondary endpoints. A dose- and time-dependent reduction in pathophysiological markers of Alzheimer's disease was observed in both trials.

Topics & Keywords

Alzheimer's disease research and treatments Dementia and Cognitive Impairment Research Cholinesterase and Neurodegenerative Diseases

Publication Details

Published in: The Journal of Prevention of Alzheimer s Disease

Volume 9, Issue 2, pp. 197-210

DOI: 10.14283/jpad.2022.30

Field-Weighted Citation Impact: 139.02

Command Palette

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease

Authors

Abstract

Topics & Keywords

Publication Details